Advances in Treatment of Atherosclerosis Targeting Lipid Metabolism and Oxidative Stress

doi:10.3969/j.issn.1673-5765.2020.08.018

Abstract

Abstract:

Atherosclerosis is a chronic inflammatory disease. Impaired lipid metabolism and oxidative stress response can accelerate the pathological process. This article introduced the treatment methods in the basic research that aim to regulate lipid metabolism and improve oxidative stress. The mechanisms that regulate lipid metabolism include: (1) The proprotein convertase subtilisin/kexin type 9 (PCSK9) small molecule inhibitor not only inhibits PCSK9 activity, but also increases LDL receptors on the surface of liver cells; (2) Nanoparticle miR-chNPs (miR206-chNPs and miR223-chNPs) promote cholesterol efflux by regulating post-transcription gene expression. The mechanisms of improving oxidative stress include: (1) Antioxidant selenium nanoparticles play a role of maintaining the redox homeostasis of the body through antioxidant selenium enzyme or selenoprotein; (2) thioredoxin 1 mimic peptide functions through its antioxidant effect and protein signal transduction; (3) histone deacetylase inhibitors inhibit the development of atherosclerotic lesions by inhibiting oxidative stress. The above methods are emerging therapeutic methods for the future treatment of atherosclerotic diseases.

Key words: Atherosclerosis; Lipid metabolism; Oxidative stress; Basic research

摘要：

动脉粥样硬化是一种慢性炎症性疾病，脂质代谢障碍和氧化应激反应加速了病变过程。本文介绍了基础研究中以调节脂质代谢和改善氧化应激为目标的治疗方法。调节脂质代谢的治疗方法包括：①前蛋白转化酶枯草溶菌素9型（PCSK9）小分子抑制剂：不仅能够抑制前蛋白转化酶枯草溶菌素9型的活性，而且能增加肝细胞表面LDL受体；②纳米颗粒miR-chNPs（miR206-chNPs和miR223- chNPs）：通过调节转录后基因表达，促进胆固醇外排。改善氧化应激的治疗方法包括：①抗氧化剂硒纳米颗粒：通过抗氧化剂硒酶或硒蛋白维持体内的氧化还原稳态；②硫氧还原蛋白1模拟肽：通过其抗氧化和蛋白质信号转导来发挥功能；③组蛋白脱乙酰酶抑制剂：通过抑制氧化应激延缓动脉粥样硬化病变形成。基于基础研究的新靶点治疗方法，是未来具有潜力的治疗动脉粥样硬化疾病的新兴方法。

关键词: 动脉粥样硬化; 脂质代谢; 氧化应激; 基础研究

CUI Liu-Ping,MA Di, CHEN Ying, XING Ying-Qi. Advances in Treatment of Atherosclerosis Targeting Lipid Metabolism and Oxidative Stress[J]. Chinese Journal of Stroke, 2020, 15(08): 910-915.

崔柳平，马迪，陈盈，邢英琦. 以脂质代谢和氧化应激为靶点的动脉粥样硬化治疗研究进展[J]. 中国卒中杂志, 2020, 15(08): 910-915.

References

[1] ROSS R. Atherosclerosis-an inflammatory disease

[J]. N Engl J Med，1999，340（2）：115-126.

[2] BELTOWSKI J，WOJCICKA G，JAMROZWISNIEWSKA

A，et al. Adverse effects of statins

mechanisms and consequences[J]. Current Drug Saf，

2009，4（3）：209-228.

[3] ODDEN M C，PLETCHER M J，COXSON P G，et

al. Cost-effectiveness and population impact of

statins for primary prevention in adults aged 75

years or older in the United States[J]. Ann Intern

Med，2015，162（8）：533-541.

[4] SCHIATTARELLA G G，PERRINO C，

MAGLIULO F，et al. Statins and the elderly：recent

evidence and current indications[J]. Aging Clin Exp

Res，2012，24（3 Suppl）：47-55.

[5] XU R X，WU Y J. Lipid-modifying drugs：

pharmacology and perspectives[J/OL]. Adv Exp Med

Biol，2020，1177：133-148[2020-01-15]. https：//doi.

org/10.1007/978-981-15-2517-9_5.

[6] INVESTIGATORS A H，BODEN W E，

PROBSTFIELD J L，et al. Niacin in patients with

low HDL cholesterol levels receiving intensive statin

therapy[J]. N Engl J Med，2011，365（24）：2255-

2267.

[7] LAVIGNE P M，KARAS R H. The current state

of niacin in cardiovascular disease prevention：a

systematic review and meta-regression[J]. J Am Coll

Cardiol，2013，61（4）：440-446.

[8] KAZI D S，MORAN A E，COXSON P G，et

al. Cost-effectiveness of PCSK9 inhibitor

therapy in patients with heterozygous familial

hypercholesterolemia or atherosclerotic

cardiovascular disease[J]. JAMA，2016，316（7）：

743-753.

[9] GUSTAFSEN C，OLSEN D，VILSTRUP J，et al.

Heparan sulfate proteoglycans present PCSK9 to the

LDL receptor[J]. Nat Commun，2017，8（1）：503.

[10] PETERSEN D N，HAWKINS J，RUANGSIRILUK

W，et al. A small-molecule anti-secretagogue of

PCSK9 targets the 80S ribosome to inhibit PCSK9

protein translation[J]. Cell Chem Biol，2016，23（11）：

1362-1371.

[11] LONDREGAN A T，WEI L Q，XIAO J，et al. Small

molecule proprotein convertase subtilisin/kexin

type 9（PCSK9）inhibitors：hit to lead optimization

of systemic agents[J]. J Med Chem，2018，61（13）：

5704-5718.

[12] RAYNER K J，SHEEDY F J，ESAU C C，et

al. Antagonism of miR-33 in mice promotes

reverse cholesterol transport and regression of atherosclerosis[J]. J Clin Invest，2011，121（7）：

2921-2931.

[13] DE AGUIAR VALLIM T Q，TARLING E，KIM T，

et al. MicroRNA-144 regulates hepatic ATP binding

cassette transporter A1 and plasma high-density

lipoprotein after activation of the nuclear receptor

farnesoid X receptor[J]. Circ Res，2013，112（12）：

1602-1612.

[14] GOEDEKE L，ROTLLAN N，CANFRÁN-DUQUE

A，et al. MicroRNA-148a regulates LDL receptor and

ABCA1 expression to control circulating lipoprotein

levels[J]. Nat Med，2015，21（11）：1280-1288.

[15] MEILER S，BAUMER Y，TOULMIN，et al.

MicroRNA 302a is a novel modulator of cholesterol

homeostasis and atherosclerosis[J]. Arterioscler

Thromb Vasc Biol，2015，35（2）：323-331.

[16] VICKERS K C，LANDSTREET S R，LEVIN M

G，et al. MicroRNA-223 coordinates cholesterol

homeostasis[J]. Proc Natl Acad Sci U S A，2014，111

（40）：14518-14523.

[17] VINOD M，CHENNAMSETTY I，COLIN S，et al.

miR-206 controls LXRα expression and promotes

LXR-mediated cholesterol efflux in macrophages[J].

Biochim Biophys Acta，2014，1841（6）：827-835.

[18] ZHONG D，HUANG G，ZHANG Y，et al.

MicroRNA-1 and microRNA-206 suppress LXRα-

induced lipogenesis in hepatocytes[J]. Cell Signal，

2013，25（6）：1429-1437.

[19] NGUYEN M A，WYATT H，SUSSER L，et al.

Delivery of microRNAs by chitosan nanoparticles to

functionally alter macrophage cholesterol efflux in

vitro and in vivo[J]. ACS Nano，2019，13（6）：6491-

6505.

[20] KATTOOR A J，POTHINENI N V K，PALAGIRI D，

et al. Oxidative stress in atherosclerosis[J/OL]. Curr

Atheroscler Rep，2017，19（11）：42[2020-01-15].

https：//doi.org/10.1007/s11883-017-0678-6.

[21] SUGAMURA K，KEANEY J F. Reactive oxygen

species in cardiovascular disease[J]. Free Radical

Biol Med，2011，51（5）：978-992.

[22] KORNFELD O S，HWANG S，DISATNIK M H，

et al. Mitochondrial reactive oxygen species at the

heart of the matter：new therapeutic approaches for

cardiovascular diseases[J]. Circ Res，2015，116（11）：

1783-1799.

[23] DOU Y，CHEN Y，ZHANG X J，et al. Nonproinflammatory

and responsive nanoplatforms

for targeted treatment of atherosclerosis[J/OL].

Biomaterials，2017，143：93-108[2020-01-15].

https：//doi.org/10.1016/j.biomaterials.2017.07.035.

[24] ALAARG A，PEREZ-MEDINA C，METSELAAR

J M，et al. Applying nanomedicine in maladaptive

inflammation and angiogenesis[J/OL]. Adv Drug

Delivery Rev，2017，119：143-158[2020-01-15].

https：//doi.org/10.1016/j.addr.2017.05.009.

[25] CHUNG E J，TIRRELL M. Recent advances in

targeted，self-assembling nanoparticles to address

vascular damage due to atherosclerosis[J]. Adv

Healthcare Mater，2015，4（16）：2408-2422.

[26] GUO L L，XIAO J Y，LIU H J，et al. Selenium

nanoparticles alleviate hyperlipidemia and vascular

injury in ApoE-deficient mice by regulating

cholesterol metabolism and reducing oxidative

stress[J]. Metallomics，2020，12（2）：204-217.

[27] WANG Y B，FU L L. Forms of selenium affect its

transport，uptake and glutathione peroxidase activity

in the Caco-2 cell model[J]. Biol Trace Elem Res，

2012，149（1）：110-116.

[28] SKALICKOVA S，MILOSAVLJEVIC V，

CIHALOVA K，et al. Selenium nanoparticles as

a nutritional supplement[J/OL]. Nutrition，2017，

33：83-90[2020-01-15]. https：//doi.org/10.1016/

j.nut.2016.05.001.

[29] MAHMOOD D F，ABDERRAZAK A，EL HADRI

K，et al. The thioredoxin system as a therapeutic

target in human health and disease[J]. Anti Redox

Signal，2013，19（11）：1266-1303.

[30] CANESI F，MATEO V，COUCHIE D，et al. A

thioredoxin-mimetic peptide exerts potent antiinflammatory，

antioxidant，and atheroprotective

effects in ApoE2. Ki mice fed high fat diet[J].

Cardiovasc Res. 2019，115（2）：292-301.

[31] COUCHIE D，VAISMAN B，ABDERRAZAK

A，et al. Human plasma thioredoxin-80 increases

with age and in ApoE-/- mice induces inflammation，

angiogenesis，and atherosclerosis[J]. Circulation，

2017，136（5）：464-475.

[32] WANG Y G，MIAO X，LIU Y C，et al.

Dysregulation of histone acetyltransferases

and deacetylases in cardiovascular diseases[J/

OL]. Oxidative Med Cell Longev，2014，

2014：641979[2020-01-15]. https：//doi.

org/10.1155/2014/641979.

[33] ZHOU B D，MARGARITI A，ZENG L F，et al. Role

of histone deacetylases in vascular cell homeostasis

and arteriosclerosis[J]. Cardiovasc Res，2011，90（3）：

413-420.

[34] XU S S，ALAM S，MARGARITI A. Epigenetics

in vascular disease - therapeutic potential of new

agents[J]. Curr Vasc Pharmacol，2014，12（1）：77-

86.

[35] CHEN F，LI X Y，AQUADRO E，et al. Inhibition of histone deacetylase reduces transcription of NADPH

oxidases and ROS production and ameliorates

pulmonary arterial hypertension[J]. Free Radic Biol

Med，2016，99：167-178[2020-01-15]. https：//doi.

org/10.1016/j.freeradbiomed.2016.08.003.

[36] MANEA S A，VLAD M L，FENYO I M，et al.

Pharmacological inhibition of histone deacetylase

reduces NADPH oxidase expression，oxidative

stress and the progression of atherosclerotic

lesions in hypercholesterolemic apolipoprotein

E-deficient mice; potential implications for

human atherosclerosis[J/OL]. Redox Biol，2020，

28：101338[2020-01-15]. https：//doi.org/ 10.1016/

j.redox.2019.101338.

[37] GRIMALDI V，VIETRI M T，SCHIANO C，et

al. Epigenetic reprogramming in atherosclerosis[J].

Curr Atheroscle Rep，2015，17（2）：476.